Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,063 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition.
Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Mishima S, et al. Among authors: nishiyama h. Int J Clin Oncol. 2023 Oct;28(10):1237-1258. doi: 10.1007/s10147-023-02397-9. Epub 2023 Aug 20. Int J Clin Oncol. 2023. PMID: 37599324 Free PMC article.
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.
Naito Y, Mishima S, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Naito Y, et al. Among authors: nishiyama h. Int J Clin Oncol. 2023 Jul;28(7):827-840. doi: 10.1007/s10147-023-02345-7. Epub 2023 May 22. Int J Clin Oncol. 2023. PMID: 37212982 Free PMC article.
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.
Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Mishima S, et al. Among authors: nishiyama h. Int J Clin Oncol. 2023 Aug;28(8):941-955. doi: 10.1007/s10147-023-02360-8. Epub 2023 Jun 10. Int J Clin Oncol. 2023. PMID: 37300720 Free PMC article.
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K, Nakanishi K, Sakai H, Tsukamoto S, Komine K, Yasuda Y, Kato T, Fujiwara Y, Koyama T, Kitamura H, Kuwabara T, Yonezawa A, Okumura Y, Yakushijin K, Nozawa K, Goto H, Matsubara T, Hoshino J, Yanagita M; Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022. Ando Y, et al. Among authors: nishiyama h. Int J Clin Oncol. 2023 Oct;28(10):1315-1332. doi: 10.1007/s10147-023-02382-2. Epub 2023 Jul 16. Int J Clin Oncol. 2023. PMID: 37453935
A nationwide, cross-sectional, web-based survey on healthcare providers' knowledge about, attitudes toward, and perceived barriers to adherence to clinical practice guidelines for anticancer drug therapy for older patients with cancer in Japan.
Matsuoka A, Shimazu T, Takahashi M, Nagashima F, Nishiyama H, Fujimori M, Ando Y. Matsuoka A, et al. Among authors: nishiyama h. J Geriatr Oncol. 2023 Jan;14(1):101399. doi: 10.1016/j.jgo.2022.10.014. Epub 2022 Nov 7. J Geriatr Oncol. 2023. PMID: 36357276
[Two Cases of Femoral Nerve Palsy after Pelvic Surgery].
Kinase S, Hoshi A, Iimura T, Sakurai H, Isoda B, Kojo K, Sakka S, Tanaka K, Ikeda A, Yoshino T, Kimura T, Kandori S, Kawahara T, Negoro H, Kojima T, Nishiyama H. Kinase S, et al. Among authors: nishiyama h. Hinyokika Kiyo. 2023 Jan;69(1):25-28. doi: 10.14989/ActaUrolJap_69_1_25. Hinyokika Kiyo. 2023. PMID: 36727458 Free article. Japanese.
Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi‑institutional retrospective study.
Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N, Obara W. Kato R, et al. Among authors: nishiyama h. Int J Clin Oncol. 2023 May;28(5):726-727. doi: 10.1007/s10147-023-02331-z. Int J Clin Oncol. 2023. PMID: 37010622 Free PMC article. No abstract available.
Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial.
Kimura T, Ishikawa H, Nagumo Y, Sekino Y, Kageyama Y, Ushijima H, Kawai T, Yamashita H, Azuma H, Nihei K, Takemura M, Hashimoto K, Maruo K, Tsuzuki T, Nishiyama H; BPT-ART Investigators Group. Kimura T, et al. Among authors: nishiyama h. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):644-651. doi: 10.1016/j.ijrobp.2023.05.013. Epub 2023 May 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 37196834 Free article. Clinical Trial.
1,063 results